Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis

Teva Pharmaceutical Industries Ltd. TEVA today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application for beclomethasone dipropionate hydrofluoroalkane, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis. Teva's NDA was submitted to the FDA on May 24, 2011.